Navigation Links
ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
Date:10/30/2010

luded as well as interim SVR rates based on data available to date; and (v) the beneficial effect of ANA598 in both CC and non-CC patients based on observations in the Phase II combination study. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2009, Form 10-Q for the quarter ended September 30, 2010 and Form 8-K filed on October 15, 2010. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Pegasys® and Copegus® are registered trademarks of Ho
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Services Industry (U.S.): Analytics, Extensive Financial ... 2021, NAIC 541380 ... Testing Laboratories, Safety and Compliance Services ...
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... North America Laparoscopes Market Outlook to ... North America Laparoscopes Market Outlook to 2020 ... Laparoscopes Market Outlook to 2020", provides key market ... report provides value, in millions of US dollars, ...
(Date:8/28/2014)... DALLAS , Aug. 28, 2014 /PRNewswire-iReach/ -- ... Poland (Photo - ... " CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Poland ... identifies key trends in the healthcare market and ... and healthcare infrastructure. Most importantly, the report provides ...
Breaking Medicine Technology:Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5
... Jan. 11 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... in San Francisco. The conference will be held January 11-14, 2010, at ... 2010, 2:00 PM Pacific Time. The conference will be webcast live with ... accessed at www.celltherapeutics.com . , , ...
... , DURHAM, N.C., Jan. 8 Oxygen Biotherapeutics, ... stock has been approved for listing on the NASDAQ Capital ... the NASDAQ is a very important milestone for our company," ... on the NASDAQ provides us with greater visibility for our ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference 2Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing 2
(Date:8/28/2014)... Blood's Thicker Than Water is based on a true ... the heart of the city. Raymond E. Blake paints this ... disrespect caused two families to collide with each other and ... Boyz and the M.O.B. Boyz clash in a rain of ... a silent terror. "Guerrilla," AKA "Real," runs his Mob family ...
(Date:8/28/2014)... August 28, 2014 Millennium Treatment Group recently ... is extremely large, and Millennium Treatment Group is working to ... that they need. , According to the National Survey ... 21 million Americans could have benefited from treatment for drug ... received help. This means that there is a large treatment ...
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... of drug use affecting users in the workplace. A ... and Drug Dependence (NCADD) states that drug abuse ... , Employees who use or are addicted to drugs ... Drug users’ activities carry over into the workplace, causing ...
(Date:8/28/2014)... 28, 2014 (HealthDay News) -- Arguments between parents may ... indicates. Parents in more than 200 families were ... At the end of each day, mothers and fathers ... with their children. On days when parents reported ... their children were also strained, according to the study ...
(Date:8/28/2014)... As the federal government plans its exit strategy from ... rethink its role in providing health care to veterans, says ... Medicine . , "To simply go on doing more of ... the Veterans Health Administration,s cost and population structure pose in ... for Health Policy & Clinical Practice, and David Auerbach, from ...
Breaking Medicine News(10 mins):Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:A VA exit strategy 2
... may extend life for those with tumors in bile duct, ... a second chemotherapy drug to the treatment regimen of people ... to new research. , This type of cancer -- which ... notoriously difficult to treat and often fatal. , "These ...
... ... fat deposits and reshapes the body. Clinically proven, the maximus system powered by TriLipo, ... inch-loss, cellulite reduction and lax skin tightening. , ... Tel Aviv, Israel (PRWEB) April 7, 2010 - ...
... Researchers from Boston University School of Medicine (BUSM) ... have discovered a new approach for identifying smokers at ... which appear in the April 7th issue of ... use a genomic approach to prevent lung cancer in ...
... Ford Hospital have found that infection with the hepatitis ... Using administrative data from more than 67,000 Henry ... period 1997-2008, 0.6% (17/3057) patients with hepatitis C infection ... the disease developed kidney cancer. After controlling ...
... American guts don,t, study finds, , WEDNESDAY, April 7 ... human intestinal tract that help everything from digesting food ... culture because of variations in diet, researchers now report. ... microbiology by researchers in France, who identified genes in ...
... Cancer cells grow so fast that they can outstrip their ... produce energy in a way that needs less oxygen but ... Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove ... that sugar supply, causing the cells to self destruct. ...
Cached Medicine News:Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 2Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 3Health News:Pollogen Launches the Maximus, Advanced Solution for Fat Reduction and Body Shaping based on Innovative TriLipo Technology 2Health News:Pollogen Launches the Maximus, Advanced Solution for Fat Reduction and Body Shaping based on Innovative TriLipo Technology 3Health News:Researchers discover new approach for identifying smokers at highest risk for developing lung cancer 2Health News:Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer 2Health News:You Are What Microbes You Eat 2Health News:You Are What Microbes You Eat 3Health News:New agent chokes off energy supply, kills cancer cells 2
... CO2 system was expressly designed to obtain ... A special source and an equally special ... create particular high energy impulses with constant ... as 'top-flat shaped') allow storage of enough ...
... PhotoLight is an exceptional condensate ... functional dimensions for ensuring a ... a constantly evolving professional market. ... working in different studios who ...
... the result of DEKA s new ... three different methods capable of restoring ... This treatment is designed to dramatically ... the combined action of a localized ...
... combines its great versatility in epilation ... with the compactness and easy-transportability of ... vascular protocols developed for Smartepil II ... is indicated for hair removal of ...
Medicine Products: